Han Chen

Dr. Han Chen


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2021 in Ear, Nose & Throat Journal
Verified
Journal Article
Open access
PDF file
HCHan Chen
Han Chen
BZBing Zhou
Bing Zhou
QHQian Huang
Qian Huang
CLCheng Li
Cheng Li
YWYubin Wu
Yubin Wu
MWMingjie Wang
Mingjie Wang
Objective: To observe the efficacy and safety of postoperative long-term low-dose oral administration of clarithromycin in patients with refractory chronic rhinosinusitis (RCRS), to explore the characteristics of postoperative microbiota in the nasal cavity in patients with RCRS, and to compare the differences and changes in microbiota in the nasal cavity before and after medication. Methods: This was a prospective, self-controlled study. Eighteen patients with RCRS who had persistent symptoms after endoscopic sinus surgery and standard therapy with normal immunoglobulin E and eosinophil level were included. Low dose (250 mg, once daily) clarithromycin was orally administrated for 12 weeks. Symptom severity and endoscopic findings were evaluated before, after 4 weeks, and 12 weeks of treatment, and nasal cavity microbiota was analyzed simultaneously. Results: A total of 18 patients with RCRS were enrolled and 17 patients completed the study. Four weeks after oral administration of clarithromycin, significant improvement was observed in subjective symptoms including nasal congestion, rhinorrhea, postnasal drip, and general discomfort, as well as endoscopic findings including general surgical cavity condition, rhinedema, and rhinorrhea ( P < .05). After continuous treatment to the 12th week, symptoms showed significant improvement compared with baseline, and endoscopic score showed significant improvement compared with both baseline and 4 weeks after treatment. Analysis of middle nasal meatus flora revealed a significant decrease of Streptococcus pneumoniae after 12 weeks of clarithromycin treatment ( P < .05), while the richness, composition, and diversity were similar before and after treatment. Patients enrolled experienced no adverse drug reaction or allergic reaction, nor clinical significant liver function impairment observed. Conclusion: Postoperative low-dose long-term oral administration of clarithromycin in patients with RCRS can improve the clinical symptoms and facilitate the mucosal epithelialization, with good tolerance and safety. The efficacy of clarithromycin in patients with RCRS may be related to its regulatory effect on nasal cavity microbiota.

31 May 2024 in Heliyon
Verified
Journal Article
Open access
HCHan Chen
Han Chen
XDXiaoyun Du
Xiaoyun Du
To delve into the expression and functions of FGF2 in patient with thyroid cancer (THCA), we conducted a systematic analysis of the association of FGF2 with immune cell infiltration, and prognosis in THCA patients. The transcription and protein levels, methylation, and biological properties of FGF2 were examined, along with its correlation with prognosis and immune cell infiltration in THCA patients using online databases UALCAN, Human Protein Atlas, Kaplan-Meier Plotter, DNMIVD, cBioPortal, GEPIA, Metascape, Linkedomics and TIMER. Clinical samples were collected for Western blot analyses. FGF2 was substantially overexpressed in the tumor group and shown correlations with age, tumor histology, nodal metastasis, and cancer stages. Moreover, higher expression of FGF2 (HR = 3.42, 95 % CI:1.57-7.44, p = 0.00099) was greatly correlated with poorer relapse-free survival in THCA patients, particularly in female patients. FGF2 methylation level was increased in the tumor group (p = 1.29E-6), and higher methylation levels of FGF2 were positively correlated with the poorer progression-free interval in THCA patients (p = 0.015). FGF2 mutations were markedly associated with shorter disease-free survival, with a mutation rate of 6 % among the total 498 THCA patients. FGF2 functions were potentially related to cell adhesion, cytokine-cytokine receptor interaction and angiogenesis. FGF2 expression showed positive correlations with the infiltration of B cells (Cor = 0.569, p = 1.04e-42), CD4+ T cells (Cor = 0.555, p = 9.43e-41), macrophages (Cor = 0.438, p = 2.94e-42), neutrophils (Cor = 0.578, p = 9.354e-45), and dendritic cells (Cor = 0.591, p = 5.00e-47). FGF2 is a potential prognostic marker in THCA patients, with its functions possibly related to cell adhesion, interaction of the cytokine-cytokine receptor, angiogenesis, and the promotion of multiple immune cell infiltration.

29 November 2024 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
HCHan Chen
Han Chen
LWLin Wang
Lin Wang
JZJisheng Zhang
Jisheng Zhang
XYXudong Yan
Xudong Yan
L姜Longgang 姜
Longgang 姜
YJYan Jiang
Yan Jiang

12 April 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
HCHan Chen
Han Chen
L姜Longgang 姜
Longgang 姜
LWLin Wang
Lin Wang
JZJisheng Zhang
Jisheng Zhang
XYXudong Yan
Xudong Yan
YJYan Jiang
Yan Jiang
Objectives: To identify the demographic characteristics and potential risk factors of invasive fungal sinusitis (IFS) patients with Coronavirus Disease in 2019 (COVID-19). Methods: Web of Science, Embase, the Cochrane Library, and PubMed were searched from database inception to August 2023 using the combination of medical searching heading terms "invasive fungal sinusitis" and "COVID-19" and their free words. The research protocol was registered on PROSPERO (CRD42023467175). Results: A total of 53 studies were included. The mean age of IFS patients with COVID-19 was 53.72 (95% credible interval [CI]: 51.08, 56.36), with 66% males (95% CI: 0.62, 0.70), and 81% diabetes (95% CI: 0.77, 0.86). The mean time from COVID-19 diagnosis to IFS onset was 19.09 days (95% CI: 16.96, 21.22). The percentage of patients with COVID-19 PCR positivity was 33% (95% CI: 0.21, 0.45). Overall, 71% of patients receiving steroid therapy during COVID-19 infection (95% CI: 0.63, 0.78). The odds ratio of diabetes mellitus, steroid administration, and COVID-19 PCR positivity were 6.09, 2.21, and 1.82, respectively. COVID-19 infection did not affect the IFS stage. Conclusion: IFS patients with COVID-19 had an average age of 53.72 years and were predominantly males, with a mean interval of 19.09 days from COVID-19 diagnosis to IFS onset. Diabetes, steroid administration, and COVID-19 PCR positivity were risk factors. (c) 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY -NC -ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

9 March 2026 in Mucosal Immunology
Verified
Journal Article
Open access
HCHan Chen
Han Chen
LWLin Wang
Lin Wang
LHLin Han
Lin Han
L姜Longgang 姜
Longgang 姜
XYXudong Yan
Xudong Yan
YJYan Jiang
Yan Jiang
Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by epithelial barrier dysfunction and type 2-dominant inflammation, yet the upstream regulatory mechanisms linking epithelial remodeling and immune activation remain poorly understood, and reliable biomarkers for eosinophilic CRSwNP (EOS CRSwNP) are limited. This study investigated the role of the sphingosine-1-phosphate (S1P)/S1P receptor (S1PR) axis in epithelial barrier dysfunction and immune inflammation, and assess its potential as an adjunctive biomarker. S1P levels were significantly elevated in both serum and nasal tissues of CRSwNP patients, especially in the eosinophilic subtype, and correlated with disease severity and epithelial-mesenchymal transition (EMT) marker expression. In vitro experiments using human nasal epithelial cells (HNEpCs and primary HNECs) showed that S1P induced EMT and impaired barrier function predominantly through S1PR3. Pharmacological inhibition and lentiviral knockdown of S1PR3 attenuated these effects. Transcriptomic analysis identified PI3K-AKT signaling as a key downstream pathway mediating S1P/S1PR3-driven epithelial dysfunction. Multiplex immunofluorescence revealed increased S1PR3 expression in epithelial cells as well as in eosinophils and group 2 innate lymphoid cells (ILC2) in human nasal polyp tissues. In a murine nasal polyp model, pharmacological inhibition of S1PR3 attenuated polyp formation, restored epithelial junction proteins, reduced eosinophil and ILC2 infiltration, and suppressed Th2-associated cytokines (IL-4, IL-5, and IL-13). Moreover, serum S1P levels closely reflected tissue expression and disease severity, when combined with peripheral eosinophil percentage, improved diagnostic performance for identifying EOS CRSwNP. Collectively, these findings demonstrate that the S1P/S1PR3 axis links epithelial barrier dysfunction with type 2 immune inflammation in CRSwNP and may represent a promising therapeutic target and adjunctive biomarker for disease stratification.

5 August 2020 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
KYKe-Da Yu
Ke-Da Yu
XWXin Wang
Xin Wang
WCWankun Chen
Wankun Chen
LFLei Fan
Lei Fan
MMMiao Mo
Miao Mo
HCHan Chen
Han Chen
We assumed that the effect of adjuvant trastuzumab on survival is mediated by the treatment time and we conducted this trial-level meta-regression to determine the appropriate length of treatment. Twelve adjuvant trastuzumab trials (from January 2000 to June 2019, consisting of 20,271 patients) were included. We considered 12-month trastuzumab treatment as the standard. The primary study endpoint was disease-free survival (DFS). By quantifying the relationship between shortened treatment time (month) and altered recurrence risk (expressed as hazard ratio), we found the regression coefficient β was 0.05 (95% confidence interval: 0.02–0.08, P = 0.002), indicating the recurrence risk would increase 5.1% for each month that treatment was shortened. Accordingly, 3, 6, and 9-month reductions in treatment time resulted in 16%, 35%, and 57% increases in recurrence risk, respectively. We revealed a significant linear association between shortened treatment time of trastuzumab and recurrence risk. The clinical duration of adjuvant trastuzumab should be tailored.